RxDoctor Payments Data

Jeffrey Krieger, MD

Gastroenterology · Fort Worth, TXNPI 1265411920

Payments from drug & device makers

$6,240in general payments, 2019–2025

Across 355 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$819
  • Johnson & Johnson$548
  • Takeda Pharmaceuticals U.S.A., Inc.$489
  • Daiichi Sankyo Inc.$285
  • Braintree Laboratories, Inc.$249
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$6,05997%
  • Education$1322%
  • Entertainment$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,240 in reported general payments places this provider in the 60th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$122,737
Medicare patients
216
Services billed
3,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase11$53,558
XifaxanRifaximin12$37,238
SutabSod Sulf/Pot Chloride/Mag Sulf27$4,374
Omeprazole201$3,332
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C21$2,972
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates38$2,371
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag19$2,362
CholestyramineCholestyramine (With Sugar)16$2,159
Famotidine73$1,083
Esomeprazole Magnesium13$867
Lansoprazole24$743
Ondansetron OdtOndansetron168$614
Pantoprazole Sodium70$597
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl16$284
Lactulose12$277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$2,395$53,55811 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$819$40,21033 claims
Braintree Laboratories, Inc.Sutab, Suflave$249$6,73646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →